#AS­CO21: Nanobi­otix says ear­ly da­ta show 'very strong' sig­nal that its nanopar­ti­cles can di­al up an­ti­tu­mor re­sponse

While can­cer im­munother­a­pies have shown promise, Nanobi­otix thinks it can use nanopar­ti­cles to di­al up the tu­mor killing ef­fect of ra­di­a­tion and check­point in­hibitors. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.